相关实验视频

Updated: Sep 18, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

向S-尼化以克服NRAS驱动的黑色素瘤中的治疗阻力

Jyoti Srivastava¹, Sanjay Premi¹

¹Department of Tumor Microenvironment and Metastasis, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.

|June 26, 2025

概括

使用氧化合成酶 (NOS) 抑制剂向蛋白质S-化,可以克服NRAS突变黑色素瘤中MEK抑制剂的耐药性. 这种方法增强了抗瘤免疫力和T细胞反应,提供了新的治疗策略.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物化学生物化学

背景情况:

发生NRAS突变的黑色素瘤对MEK抑制剂表现出耐药性,限制了治疗选择.
蛋白质S-化是MEK-ERK信号传递和黑色素瘤中的免疫逃避的关键调节者.
在这种癌症类型中,S-化维持了瘤原性信号传递,并减少了免疫原性细胞死亡.

研究的目的:

调查蛋白质S-化在NRAS突变黑色素瘤中的作用.
探索向S-化的潜力,以克服治疗耐药性.
评估氧化合成酶 (NOS) 抑制剂对瘤免疫力的影响.

主要方法:

使用了临床前模型,包括免疫原性小鼠模型和患者衍生的黑色素瘤细胞.
研究了NOS抑制剂 (L-NAME,L-NMMA,1400w) 对MEK-ERK信号传递的影响.
评估了树突细胞激活和CD8+T细胞透的变化.
探索了S-化在巨介导免疫监测中的作用.

主要成果:

用NOS抑制剂向S-化,在临床前模型中恢复了对MEK抑制剂的敏感性.
抑制NOS促进了树突细胞的激活,并增强了CD8+ T细胞的透.
鉴定出S-化是维持瘤信号和免疫逃避的关键机制.

结论:

通过NOS抑制进行氧还原调节是克服NRAS突变黑色素瘤治疗耐药性的有希望的策略.
将氧化还原调制与向和免疫疗法结合起来,可以重新编程瘤免疫微环境.
这种方法有可能增强细胞毒性T细胞反应,并改善NRAS驱动癌症的免疫治疗结果.

关键词:

在MEK-ERK的信号中,有MEK-ERK的信号.发生NRAS突变的黑色素瘤.通过S-化化.药物耐药性耐药性药物耐药性免疫逃避免疫逃避免疫原性细胞死亡氧化还原调节的调节方法有针对性的治疗.瘤微环境是一个微环境.

更多相关视频

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...